Treatment of neonatal jaundice - more than phototherapy and exchange transfusions

Yıl 2010, Cilt: 15 Sayı: 4, 175 - 185, 17.01.2013

Marie Andersen Erlandsen Thor Willy Ruud Hansen

Öz

Abstract. Jaundice is the most common reason for doing blood tests and starting therapy in newborn infants. In some neonates serum bilirubin levels may become excessively high, and in rare instances this may lead to brain damage (kernicterus). In such cases it is important to start treatment quickly. Herein we will discuss various approaches through which serum bilirubin levels may be reduced, thus potentially preventing brain damage. This paper is based on relevant publications found through a Medline search, from which a selection was made based on the authors’ prior knowledge of and experience in the field. Case histories are used to illustrate the important points. Neonatal jaundice always has a foundation in normal physiology. However, the degree of jaundice may be accentuated by a number of pathological processes. These include hematomas and other occult hemorrhage, AB0- and Rhesus incompatibility, and increased enterohepatic circulation of bilirubin. In addition, genetic conditions such as galactosemia, hemolytic anemias, and Gilbert and Crigler-Najjar syndromes can significantly increase jaundice in newborn infants. Neonatal jaundice can be treated in several ways, including phototherapy, exchange transfusion, breast milk substitutes, and drugs (e.g. intravenous immune globulin and phenobarbital). By employing such therapies individually or in combination, it is possible to achieve rapid reductions of dangerously high bilirubin levels, and thus reduce the risk of sequelae. It is important to keep in mind that factors which may be unknown at the time of discharge from hospital or birthing unit can contribute to significant increases in total serum bilirubin levels after discharge. It is therefore important to evaluate an infant’s risk status prior to discharge. Written therapeutic guidelines for professionals are useful adjuncts in management, and oral and/or written orientation in terms and language which the parents can understand will help them as far as the post-discharge management. A written orientation in the form of a brief handout may also be a useful tool for educating parents prior to discharge.

Key words: Newborn, jaundice, neonatal, therapy, phototherapy, pharmacology, intravenous immune globulin

Anahtar Kelimeler

Newborn, jaundice, neonatal, therapy, phototherapy, pharmacology, intravenous immune globulin

Kaynakça

• Fok TF. Neonatal jaundice-traditional Chinese medicine approach. J Perinatol 2001; 21: S98-S100.
• Metlinger B. Ein regiment der jungen kinder. Wie man sy halten und erziechen sol von irer gepurt biß zu iren tagen komen. Augsburg, 1473.
• Orth J. Ueber das Vorkommen von Bilirubinkrystallen bei neugeborenen Kindern. Virchows Arch Pathol Anat 1875; 63: 447-462.
• Schmorl CG. Zur Kenntnis des Ikterus neonatorum, insbesondere der dabei auftretenden Gehirnveränderungen. Verh Dtsch Pathol Ges 1904; 6: 109-115.
• Guthrie L. A case of kernicterus associated with choreiform movements. Proc Royal Soc Med 1914; 7: 86-88.
• Zimmerman HM, Yannet H. Kernicterus, jaundice of the nuclear masses of the brain. Am J Dis Child 1933; 45: 740-759.
• Pragh Rv. Diagnosis of kernicterus in the neonatal period. Pediatrics 1961; 28: 870-876.
• AAP Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297-316.
• Harris MC, Bernbaum JC, Polin JR, Zimmerman R, Polin RA. Developmental breastfed term and near-term infants with marked hyperbilirubinemia. Pediatrics 2001; 107: 1075- 1080. follow-up of
• Hansen TWR, Nietsch L, Norman E, et al. Apparent reversibility of acute intermediate phase bilirubin encephalopathy. Acta Paediatrica 2009 (DOI:10.1111/j.1651-2227.2009.01409.x)
• Hansen TWR, Paulsen BS: Treatment of neonatal jaundice in 18th and 19th century Europe. Pediatr Res 2003; 53: 304A.
• Hart AP. Familial icterus gravis of the newborn and its treatment. Can Med Assoc J 1925; 15: 1008-1011.
• Wallerstein H. Treatment of severe erythroblastosis by simultaneous removal and replacement of blood of the newborn. Science 1946; 103: 583-584.
• Diamond LK. Erythroblastosis foetalis or haemolytic disease of the newborn. Proc. Royal Soc Med 1947: 40: 546-559.
• Diamond LK, Allen FH, Thomas WO. Erythroblastosis fetalis. VII. Treatment with exchange transfusion. N Engl J Med 1951; 244: 39- 49.
• Mollison PL, Cutbush M. Haemolytic disease of the newborn. In: Recent advances in pediatrics. (Ed. Gairdner D), P.Blakiston and Son, New York, NY, USA, 1954.
• Cremer RJ, Perryman PW, Richards DH. Influence of light on the hyperbilirubinemia of infants. Lancet 1958; 1: 1094-1097.
• Huizing KMN, Rİislien J, Hansen TWR. Intravenous immunoglobulin reduces the need for exchange transfusions in Rhesus and ABO incompatibility. Acta Paediatr 2008; 97: 1362-1365.
• Hansen, TWR. Therapeutic practices in neonatal jaundice: An international survey. Clin Pediatr 1996; 35: 309-316.
• Maisels MJ. Jaundice. In: Avery’s Neonatology. Pathophysiology and management of the newborn. (Eds. MacDonald MG, Mullett MD, Seshia MMK), Philadelphia, Lippincott, Williams & Wilkins, 2005, pp: 768-846.
• Roy-Chowdhury N, Deocharan B, Bejjanki HR, et al. Presence of genetic marker for Gilbert syndrome is associated with increased level and duration of neonatal jaundice. Acta Paediatr 2002; 91: 100-101.
• Gourley GR, Li Z, Kreamer B, et al. A controlled, randomized double-blind trial of prophylaxis against jaundice among breastfed newborns. Pediatrics 2005;116: 385-389.
• Gourley GR, Arend RA. Beta-glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies. Lancet 1986; 1: 644-646.
• McDonagh AF, Palma LA, Lightner DA. Blue light and bilirubin excretion. Science 1980; 208: 145-151.
• Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. New Engl J Med 2008; 358: 920- 928.
• Maisels MJ, Kring E. Rebound in serum bilirubin level following intensive phototherapy. Arch Pediatr Adolesc Med 2002; 156: 669-672.
• Tan KL. The nature of the dose-response relationship of phototherapy for neonatal hyperbilirubinemia. J Pediatr 1977; 90: 448-452.
• Mreihil K, McDonagh A, Nakstad B, Hansen TWR. Early isomerization of bilirubin in intensive phototherapy of neonatal jaundice. Pediatr Res 2010; 67: 656-9.
• Ebbesen F, Madsen P, Stovring S, Hundborg H, Agati G. Therapeutic effect of turquoise blue light with equal irradiance in preterm infants with jaundice. Acta Paediatr 2007; 96: 837-841.
• Tan KL. Efficacy of fluorescent daylight, blue, and green lamps in the management of nonhemolytic hyperbilirubinemia. J Pediatr 1989; 114: 132-137.
• Ennever JF, Knox I, Speck WT. Differences in bilirubin isomer composition in infants treated with green and white light phototherapy. J Pediatr 1986; 109: 119-122.
• Maisels MJ. Why use homeopathic doses of phototherapy? Pediatrics 1996; 98: 283-287.
• De Carvalho M, De Carvalho D, Trzmielina S, Lopes JMA, Hansen TWR. Intensified phototherapy using daylight fluorescent lamps. Acta Paediatr 1999; 88: 768-771.
• Meslo M, Tveiten L, Hansen TWR. Effektivisering av lysbehandling med enkle midler. Jordmorbladet 2000; 7: 18-21.
• Djokomuljanto S, Quah BS, Surini Y, et al. Efficacy of phototherapy for neonatal jaundice is increased by the use of low-cost white reflecting curtains. Arch Dis Child 2006; 91: F439-F442.
• Christensen T, Amundsen I, Kinn G, et al. Terapienheter og belysningsforhold ved lysbehandling av nyfİdte med hyperbilirubinemi. Østerås, Statens Institutt for Strålehygiene,1992: 2.
• Wiese G, Wiese F. Über die raumliche Verteilung der Lichtintensität unter einer Phototherapie- Halogenlampe. Monatsschr Kinderheilk 1985; 133: 102-105.
• Kjartansson S, Hammarlund K, Sedin G: Insensible water loss from the skin during phototherapy term and preterm infants. Acta Paediatr 81: 764-768, 1992. in
• Gottstein R, Cooke RWI. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2003; 88: 6-10.
• Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10- year prospective observational study. Pharmacoepidemiol Drug Saf 2007; 16: 1038-1047.
• Gourley GR, Kreamer B, Cohnen M, et al. Neonatal Jaudice and Diet. Arch Pediatr Adolesc Med 1999; 153: 184-188.
• Jansen PL. Diagnosis and management of Crigler- Najjar syndrome. Eur J Pediatr 1999; 2: 89-94.
• Lazar L, Litwin A, Merlob P. Phototherapy for neonatal nonhemolytic hyperbilirubinemia: Analysis of rebound and indications for discontinuing therapy. Clin Pediatr 1993; 32: 264-267.
• Volpe JJ. Neurology of the newborn, 5th Edition. Saunders Elsevier, Philadelphia, 2008.
• Watchko JF, Daood MJ, Biniwale M. Understanding neonatal hyperbilirubinaemia in the era of genomics. Semin Neonatol 2002; 7: 143-152.
• Bhutani VK, Johnson L. A proposal to prevent severe neonatal hyperbilirubinemia and kernicterus. J Perinatol 2009; 1: S61-S67.